Arkolith/Insider Trading/REPH/Form 4

Enloe J David JR

Chief Executive Officer, DirectorRecro Pharma, Inc. (REPH) · full profile →Form 4 · filed Jan 24, 2022
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
3
2 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jan 20, 2022Grant(A)303K—$0524K
Jan 20, 2022Grant(A)66K——221K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jan 20, 2022Grant(A)442K—$0442K

Transaction Codes

A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0000899243-22-003083) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML